Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

NCT00142129 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom's Macroglobulinemia
Lymphoplasmacytic Lymphoma

Interventions

DRUG: Bortezomib (Velcade)

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]